Undisclosed financial ties between guideline writers and pharmaceutical companies: A cross-sectional study across 10 disease categories

Ray Moynihan, Alexandra Lai, Huw Jarvis, Geraint Duggan, Stephanie Goodrick, Elaine Beller, Lisa Bero

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)
54 Downloads (Pure)

Abstract

Objectives To investigate the proportion of potentially relevant undisclosed financial ties between clinical practice guideline writers and pharmaceutical companies. Design Cross-sectional study of a stratified random sample of Australian guidelines and writers. Setting Guidelines available from Australia's National Health and Medical Research Council guideline database, 2012-2014, stratified across 10 health priority areas. Population 402 authors of 33 guidelines, including up to four from each area, dependent on availability: Arthritis/musculoskeletal (3); asthma (4); cancer (4); cardiovascular (4); diabetes (4); injury (3); kidney/urogenital (4); mental health (4); neurological (1); obesity (1). For guideline writers with no disclosures, or who disclosed no ties, a search of disclosures in the medical literature in the 5 years prior to guideline publication identified potentially relevant ties, undisclosed in guidelines. Guidelines were included if they contained recommendations of medicines, and writers included if developing or writing guidelines. Main outcome measures Proportions of guideline writers with potentially relevant undisclosed financial ties to pharmaceutical companies active in the therapeutic area; proportion of guidelines including at least one writer with a potentially relevant undisclosed tie. Results 344 of 402 writers (86%; 95% CI 82% to 89%) either had no published disclosures (228) or disclosed they had no ties (116). Of the 344 with no disclosed ties, 83 (24%; 95% CI 20% to 29%) had potentially relevant undisclosed ties. Of 33 guidelines, 23 (70%; 95% CI 51% to 84%) included at least one writer with a potentially relevant undisclosed tie. Writers of guidelines developed and funded by governments were less likely to have undisclosed financial ties (8.1%vs30.6%; risk ratio 0.26; 95% CI 0.13 to 0.53; p<0.001). Conclusions Almost one in four guideline writers with no disclosed ties may have potentially relevant undisclosed ties to pharmaceutical companies. These data confirm the need for strategies to ensure greater transparency and more independence in relationships between guidelines and industry.

Original languageEnglish
Article numbere025864
JournalBMJ Open
Volume9
Issue number2
DOIs
Publication statusPublished - 1 Feb 2019

Fingerprint

Cross-Sectional Studies
Guidelines
Pharmaceutical Preparations
Disclosure
Health Priorities
Practice Guidelines
Arthritis
Publications
Biomedical Research
Industry
Mental Health
Asthma
Obesity
Odds Ratio
Outcome Assessment (Health Care)
Databases
Kidney

Cite this

Moynihan, Ray ; Lai, Alexandra ; Jarvis, Huw ; Duggan, Geraint ; Goodrick, Stephanie ; Beller, Elaine ; Bero, Lisa. / Undisclosed financial ties between guideline writers and pharmaceutical companies : A cross-sectional study across 10 disease categories. In: BMJ Open. 2019 ; Vol. 9, No. 2.
@article{d43e1b58de614d7888d77c648655d62a,
title = "Undisclosed financial ties between guideline writers and pharmaceutical companies: A cross-sectional study across 10 disease categories",
abstract = "Objectives To investigate the proportion of potentially relevant undisclosed financial ties between clinical practice guideline writers and pharmaceutical companies. Design Cross-sectional study of a stratified random sample of Australian guidelines and writers. Setting Guidelines available from Australia's National Health and Medical Research Council guideline database, 2012-2014, stratified across 10 health priority areas. Population 402 authors of 33 guidelines, including up to four from each area, dependent on availability: Arthritis/musculoskeletal (3); asthma (4); cancer (4); cardiovascular (4); diabetes (4); injury (3); kidney/urogenital (4); mental health (4); neurological (1); obesity (1). For guideline writers with no disclosures, or who disclosed no ties, a search of disclosures in the medical literature in the 5 years prior to guideline publication identified potentially relevant ties, undisclosed in guidelines. Guidelines were included if they contained recommendations of medicines, and writers included if developing or writing guidelines. Main outcome measures Proportions of guideline writers with potentially relevant undisclosed financial ties to pharmaceutical companies active in the therapeutic area; proportion of guidelines including at least one writer with a potentially relevant undisclosed tie. Results 344 of 402 writers (86{\%}; 95{\%} CI 82{\%} to 89{\%}) either had no published disclosures (228) or disclosed they had no ties (116). Of the 344 with no disclosed ties, 83 (24{\%}; 95{\%} CI 20{\%} to 29{\%}) had potentially relevant undisclosed ties. Of 33 guidelines, 23 (70{\%}; 95{\%} CI 51{\%} to 84{\%}) included at least one writer with a potentially relevant undisclosed tie. Writers of guidelines developed and funded by governments were less likely to have undisclosed financial ties (8.1{\%}vs30.6{\%}; risk ratio 0.26; 95{\%} CI 0.13 to 0.53; p<0.001). Conclusions Almost one in four guideline writers with no disclosed ties may have potentially relevant undisclosed ties to pharmaceutical companies. These data confirm the need for strategies to ensure greater transparency and more independence in relationships between guidelines and industry.",
author = "Ray Moynihan and Alexandra Lai and Huw Jarvis and Geraint Duggan and Stephanie Goodrick and Elaine Beller and Lisa Bero",
year = "2019",
month = "2",
day = "1",
doi = "10.1136/bmjopen-2018-025864",
language = "English",
volume = "9",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "2",

}

Undisclosed financial ties between guideline writers and pharmaceutical companies : A cross-sectional study across 10 disease categories. / Moynihan, Ray; Lai, Alexandra; Jarvis, Huw; Duggan, Geraint; Goodrick, Stephanie; Beller, Elaine; Bero, Lisa.

In: BMJ Open, Vol. 9, No. 2, e025864, 01.02.2019.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Undisclosed financial ties between guideline writers and pharmaceutical companies

T2 - A cross-sectional study across 10 disease categories

AU - Moynihan, Ray

AU - Lai, Alexandra

AU - Jarvis, Huw

AU - Duggan, Geraint

AU - Goodrick, Stephanie

AU - Beller, Elaine

AU - Bero, Lisa

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Objectives To investigate the proportion of potentially relevant undisclosed financial ties between clinical practice guideline writers and pharmaceutical companies. Design Cross-sectional study of a stratified random sample of Australian guidelines and writers. Setting Guidelines available from Australia's National Health and Medical Research Council guideline database, 2012-2014, stratified across 10 health priority areas. Population 402 authors of 33 guidelines, including up to four from each area, dependent on availability: Arthritis/musculoskeletal (3); asthma (4); cancer (4); cardiovascular (4); diabetes (4); injury (3); kidney/urogenital (4); mental health (4); neurological (1); obesity (1). For guideline writers with no disclosures, or who disclosed no ties, a search of disclosures in the medical literature in the 5 years prior to guideline publication identified potentially relevant ties, undisclosed in guidelines. Guidelines were included if they contained recommendations of medicines, and writers included if developing or writing guidelines. Main outcome measures Proportions of guideline writers with potentially relevant undisclosed financial ties to pharmaceutical companies active in the therapeutic area; proportion of guidelines including at least one writer with a potentially relevant undisclosed tie. Results 344 of 402 writers (86%; 95% CI 82% to 89%) either had no published disclosures (228) or disclosed they had no ties (116). Of the 344 with no disclosed ties, 83 (24%; 95% CI 20% to 29%) had potentially relevant undisclosed ties. Of 33 guidelines, 23 (70%; 95% CI 51% to 84%) included at least one writer with a potentially relevant undisclosed tie. Writers of guidelines developed and funded by governments were less likely to have undisclosed financial ties (8.1%vs30.6%; risk ratio 0.26; 95% CI 0.13 to 0.53; p<0.001). Conclusions Almost one in four guideline writers with no disclosed ties may have potentially relevant undisclosed ties to pharmaceutical companies. These data confirm the need for strategies to ensure greater transparency and more independence in relationships between guidelines and industry.

AB - Objectives To investigate the proportion of potentially relevant undisclosed financial ties between clinical practice guideline writers and pharmaceutical companies. Design Cross-sectional study of a stratified random sample of Australian guidelines and writers. Setting Guidelines available from Australia's National Health and Medical Research Council guideline database, 2012-2014, stratified across 10 health priority areas. Population 402 authors of 33 guidelines, including up to four from each area, dependent on availability: Arthritis/musculoskeletal (3); asthma (4); cancer (4); cardiovascular (4); diabetes (4); injury (3); kidney/urogenital (4); mental health (4); neurological (1); obesity (1). For guideline writers with no disclosures, or who disclosed no ties, a search of disclosures in the medical literature in the 5 years prior to guideline publication identified potentially relevant ties, undisclosed in guidelines. Guidelines were included if they contained recommendations of medicines, and writers included if developing or writing guidelines. Main outcome measures Proportions of guideline writers with potentially relevant undisclosed financial ties to pharmaceutical companies active in the therapeutic area; proportion of guidelines including at least one writer with a potentially relevant undisclosed tie. Results 344 of 402 writers (86%; 95% CI 82% to 89%) either had no published disclosures (228) or disclosed they had no ties (116). Of the 344 with no disclosed ties, 83 (24%; 95% CI 20% to 29%) had potentially relevant undisclosed ties. Of 33 guidelines, 23 (70%; 95% CI 51% to 84%) included at least one writer with a potentially relevant undisclosed tie. Writers of guidelines developed and funded by governments were less likely to have undisclosed financial ties (8.1%vs30.6%; risk ratio 0.26; 95% CI 0.13 to 0.53; p<0.001). Conclusions Almost one in four guideline writers with no disclosed ties may have potentially relevant undisclosed ties to pharmaceutical companies. These data confirm the need for strategies to ensure greater transparency and more independence in relationships between guidelines and industry.

UR - http://www.scopus.com/inward/record.url?scp=85061296254&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2018-025864

DO - 10.1136/bmjopen-2018-025864

M3 - Article

VL - 9

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 2

M1 - e025864

ER -